Skip to main content
Pacira BioSciences, Inc. logo

Pacira BioSciences, Inc. — Investor Relations & Filings

Ticker · PCRX ISIN · US6951271005 LEI · 549300P56LERYBDHCF69 US Manufacturing
Filings indexed 1,216 across all filing types
Latest filing 2025-11-13 Director's Dealing
Country US United States of America
Listing US PCRX

About Pacira BioSciences, Inc.

https://www.pacira.com/

Pacira BioSciences, Inc. is a pharmaceutical company that develops, commercializes, and manufactures non-opioid pain management and regenerative health solutions. The company's mission is to provide alternatives to opioids by delivering innovative, precise, and targeted therapies. Its products and research pipeline address a diverse range of needs, including postsurgical, chronic, and musculoskeletal pain. Pacira is also focused on developing advanced solutions, including gene therapy, to address unmet needs in pain management.

Recent filings

Filing Released Lang Actions
FORM 4
Director's Dealing
2025-11-13 English
Major Shareholding Notification 2025
Major Shareholding Notification
2025-11-13 English
Major Shareholding Notification 2025
Major Shareholding Notification
2025-11-11 English
Regulatory Filings 2025
Regulatory Filings
2025-11-10 English
10-Q
Interim / Quarterly Report Q3 2025
2025-11-06 English
8-K
Earnings Release Classification · 95% confidence The document is a Form 8-K filed with the SEC, which is a current report used to announce major events. The text specifically mentions "Item 2.02. Results of Operations and Financial Condition" and states that a press release announcing financial results for the third quarter ended September 30, 2025, is furnished as an exhibit. The document itself does not contain detailed financial statements or substantive financial data but rather references an earnings press release. The length of the document is 3402 characters, which is relatively short and consistent with a current report filing rather than a full financial report. According to the classification rules, an initial announcement of quarterly financial results (key highlights only) corresponds to an Earnings Release (ER). Therefore, this document should be classified as an Earnings Release (ER).
2025-11-06 English

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.